3/26
04:13 am
armp
Armata Pharmaceuticals GAAP EPS of -$3.42, revenue of $1.1M [Seeking Alpha]
Medium
Report
Armata Pharmaceuticals GAAP EPS of -$3.42, revenue of $1.1M [Seeking Alpha]
3/25
04:05 pm
armp
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
High
Report
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
3/19
07:00 am
armp
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
Medium
Report
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
3/16
01:31 pm
armp
Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape [Yahoo! Finance]
Low
Report
Pseudomonal Infections Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 10+ Leading Players Wheeling the Therapeutics Landscape [Yahoo! Finance]
3/12
03:41 pm
armp
Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags [Seeking Alpha]
Medium
Report
Armata Pharmaceuticals: Intriguing Antibiotic Adjunct, But Too Many Potential Red Flags [Seeking Alpha]
3/2
10:42 am
armp
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod [Yahoo! Finance]
Medium
Report
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod [Yahoo! Finance]
2/23
07:00 am
armp
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
Medium
Report
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02